Recipharm and Altus Formulation collaborate to offer novel drug delivery technologies for value added medicines
Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery technologies and products. Under the terms of the agreement, Recipharm will co-develop new value added medicines for its customers utilising Altus’ patented INTELLITAB™ and FLEXITAB™ drug delivery technologies. INTELLITAB is a novel misuse and abuse deterrent